Current Atherosclerosis Reports

Article	Citations
Revascularization Options for Left Main Disease: What Clinicians Need to Know	169
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions	154
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	125
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management	122
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes	117
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis	98
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?	73
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease	70
The Role of the PI3K/Akt/mTOR Pathway in Atherosclerosis: Mechanisms, Therapeutic Potential, and Emerging Targeted Treatments	68
The Effects of FABP4 on Cardiovascular Disease in the Aging Population	61
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators	60
Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis	52
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice	46
Salutary Effects of Nutritional Ketosis for the Diseased Human Heart	45
Spontaneous Coronary Artery Dissection (SCAD): Unveiling the Enigma of the Unexpected Coronary Event	44
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review	43
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease	41
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?	39
Inflammation in the Peri-ACS Period: Ready for Prime Time?	39
Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease	38
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?	38
Percutaneous Coronary Interventions in Women	38
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women	36
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?	36
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention	36

Lipoprotein(a): from Causality to Treatment	35
The Emerging Specialty of Cardio-Rheumatology	34
Myeloid Cells in Abdominal Aortic Aneurysm	33
The Role of Sleep in Cardiovascular Disease	33
Importance of Nutrition Security to CVD Prevention Efforts in the USA	32
The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger	32
Low LDL-C: Is It all Good News?	32
In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?	32
Role of RNA-binding Proteins in Regulating Cell Adhesion and Progression of the Atherosclerotic Plaque and Plaque Erosion	31
Can Clinical Biomarkers Guide Optimal Therapeutic Selection in Type 2 Diabetes Mellitus? A Scoping Review	30
Implementing Reporting Standards for Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease	28
Effects of Omega-3 Fatty Acids on Flow-mediated Dilatation and Carotid Intima Media Thickness: A Meta-analysis	28
Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations: What Clinicians Need to Know?	27
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment	27
Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know	26
Stress, Vascular Smooth Muscle Cell Phenotype and Atherosclerosis: Novel Insight into Smooth Muscle Cell Phenotypic Transition in Atherosclerosis	26
Exploring the Role of SPARC in Atherosclerosis: Mechanisms and Potential Implications	25
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference	24
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity	23
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?	23
Transforming Population Health Screening for Atherosclerotic Cardiovascular Disease with AI-Enhanced ECG Analytics: Opportunities and Challenges	23
Is Family History for the Management of Cardiovascular Health in Youth Still Relevant in Clinical Practice?	22
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 European Society of Cardiology Conference	22
Gene Regulatory Networks in Coronary Artery Disease	22
Factors Affecting Circulating Phytosterol Levels: Toward an Integrated Understanding of Atherogenicity and Atheroprotection by Dietary and Circulating Phytosterols	22
Membrane Cholesterol Interactions with Proteins in Hypercholesterolemia-Induced Endothelial Dysfunction	22
Is There a Role for Imaging Youth at Risk of Atherosclerosis?	22
Noninvasive Atherosclerotic Phenotyping: The Next Frontier into Understanding the Pathobiology of Coronary Artery Disease	22
Clinical Management of Dyslipidemia in Infants and Toddlers	21
Brief Review: Racial and Ethnic Disparities in Cardiovascular Care with a Focus on Congenital Heart Disease and Precision Medicine	21
Cardiovascular Disease in the Middle East and North Africa, 1990–2021: Burden, Trends, and Risk Factors	21
HIV and Cardiovascular Disease Burden in Young Adults (18–25 years): A Review of Current Evidence	21
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American College of Cardiology Conference	20
Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults	20
Natural Sirtuin1 Activators and Atherosclerosis: an Overview	20
Expanding Clinical Indications for Cardiac CT: A Review of Its Current Utility in American and European Guidelines	20
What Causes Premature Coronary Artery Disease?	20
Cardiovascular Health and Disease in the Pakistani American Population	20
High Density Lipoprotein Particle Composition, Functionality, Deficiency, and Atherosclerotic Cardiovascular Disease Risk: A Review	19
Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population	19
A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms	18
Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field	18
Correlation Between Oral Bacteria and Atherosclerotic Thrombotic Disease: Advances in Animal Model Studies	18
Utility of FFRCT in Patients with Chest Pain	18
Targeting the Gut Microbiome to Treat Cardiometabolic Disease	18
Extra-coronary Calcification and Cardiovascular Events: What Do We Know and Where Are We Heading?	17
Fixed Combination for the Treatment of Dyslipidaemia	17
Anti-Inflammatory Lipid Mediators from Polyunsaturated Fatty Acids: Insights into their Role in Atherosclerosis Microenvironments	17
Circular RNA role in Atherosclerosis Development and Progression	17
The Role of Lysyl Oxidase in the Pathological Stage of Atherosclerosis: Structural Stabilizer or Disease Driver?	17

Serial Coronary CTA for Monitoring Response to Lipid-Lowering Therapy: A Narrative Review	16
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk	16
Combined Dyslipidemia in Children and Adolescents: a Proposed New Management Approach	16
Dietary Management of Atherogenic Dyslipidemia	16
Apheresis: What Should a Clinician Know?	15
European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges	15
Pregnancy Complications and Long-Term Atherosclerotic Cardiovascular Disease Risk	15
Unraveling the miRNA Puzzle in Atherosclerosis: Revolutionizing Diagnosis, Prognosis, and Therapeutic Approaches	15
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions	15
Cardiovascular Disease Burden among African Migrants	14
The TICE Pathway: Mechanisms and Potential Clinical Applications	14
Statins as Modulators of Epithelial to Mesenchymal Transition in Cardiovascular-Kidney-Metabolic Syndrome: a Comprehensive Review of Mechanisms and Therapeutic Implications	14
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia	14
Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation	13
How to Handle Elevated Triglycerides: Life after PROMINENT	13
CETP Inhibitors: Should We Continue to Pursue This Pathway?	13
Psychological Health and Ischemic Heart Disease in Women: A Review of Current Evidence and Clinical Considerations across the Healthspan	13
Obicetrapib—the Rebirth of CETP Inhibitors?	13
Should Familial Hypercholesterolaemia Be Included in the UK Newborn Whole Genome Sequencing Programme?	13
Coronary and Extra-coronary Subclinical Atherosclerosis to Guide Lipid-Lowering Therapy	13
S-Nitrosylation: Mechanistic Links between Nitric Oxide Signaling and Atherosclerosis	13
HDL as a Treatment Target: Should We Abandon This Idea?	13
Statin Use and Hyperglycemia: Do Statins Cause Diabetes?	13
Unveiling the Sex-Based Divide: Exploring Sex Differences in Peripheral Artery Disease	13
Artificial Intelligence-Enabled Point-of-Care Echocardiography: Bringing Precision Imaging to the Bedside	12
An Update on Nutrition Guidance for Cardiovascular Health	12
Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment	12
Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?	12
Do Statins Affect Cognitive Health? A Narrative Review and Critical Analysis of the Evidence	12
The Atherosclerotic Plaque Microenvironment as a Therapeutic Target	12
Gene Editing for the Treatment of Hypercholesterolemia	12
LDL Transcytosis by the Arterial Endothelium—Atherosclerosis by a Thousand Cuts?	12
Advances, Challenges, and Progress in Cardiac Rehabilitation in Chronic CVD Management	12
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes	11
Family Meals and Cardiometabolic Risk Factors in Young Children	11
Update on Sitosterolemia and Atherosclerosis	11
Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?	11
Mechanisms Behind NAFLD: a System Genetics Perspective	11
Myocardial Bridge and Atherosclerosis, an Intimal Relationship	11
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy	10
Health Literacy is Essential to ASCVD Prevention in Youth	10
Biomarkers Differentiating Plaque Erosion from Stable Plaque	10
The Management of Hypercholesterolemia in Patients with Neuromuscular Disorder	10
“Anti-inflammatory Therapies in Atherosclerosis – Where are we going?”	10
Ancestral Variation in Lp(a): Epidemiology, Isoform Diversity, and Testing	10
Are Glucagon-Like Peptide 1 Receptor Agonists and Bariatric Surgery the Answer to Childhood Obesity?	10
Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes	10
Transitioning Adolescents and Young Adults with Lipid Disorders to Adult Health Care	10
Correction to: Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	10
JAM-A: Adhesion Receptor and Signaling Regulator in Atherosclerosis	10
Correction to: Built Environment and Cardiovascular Diseases – Insights from a Global Review	10
Eggs and Cardiovascular Disease Risk: An Update of Recent Evidence	10
Sport as Medicine for Dyslipidemia (and Other Risk Factors)	10
Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)	9
Double-Trouble: Atherosclerotic Risk Factors and Congenital Heart Disease	9
Impact of Sex Differences on Lipids and Statin Utilization	9
Rap1 in the Context of PCSK9, Atherosclerosis, and Diabetes	9
Familial Combined Hyperlipidemia: Myth or Reality?	9
Invasive Coronary Assessment in Myocardial Ischemia with No Obstructive Coronary Arteries	9
Tackling the Cardio-Kidney-Metabolic Burden in Cancer	9
Statin Intolerance: an Overview of US and International Guidance	9
ADAMTS7: a Novel Therapeutic Target in Atherosclerosis	9
Effects of the COVID-19 Pandemic on Pediatric and Adolescent ASCVD Risk Factors	9
Incidental Finding of Coronary and Non-Coronary Artery Calcium: What Do Clinicians Need To Know?	9
Built Environment and Cardiovascular Diseases – Insights from a Global Review	9
Updates in Small Interfering RNA for the Treatment of Dyslipidemias	9
The Pandemic of Coronary Heart Disease in the Middle East and North Africa: What Clinicians Need to Know	8
Insight into the Mechanistic role of Colchicine in Atherosclerosis	8
Sex-based Differences in Complications Following Percutaneous Coronary Interventions	8
The Role of Genetics in Advancing Cardiometabolic Drug Development	8
PCSK9 and Coronary Artery Plaque—New Opportunity or Red Herring?	8
Lp(a): A Rapidly Evolving Therapeutic Landscape	8
N-3 Fatty Acids (EPA and DHA) and Cardiovascular Health - Updated Review of Mechanisms and Clinical Outcomes	8
Mechanosensing and Mechanosignal Transduction in Atherosclerosis	8
Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus	8
Medical Nutrition Therapy Provided by Dietitians is Effective and Saves Healthcare Costs in the Management of Adults with Dyslipidemia	8
Updates in Drug Treatment of Severe Hypertriglyceridemia	8
AI in Adipose Imaging: Revolutionizing Visceral Adipose Tissue, Ectopic Fat, and Cardiovascular Risk Assessment	8
Predictive Modeling and Structure Analysis of Genetic Variants in Familial Hypercholesterolemia: Implications for Diagnosis and Protein Interaction Studies	8
The Role of Cardiac PET in Diagnosis and Prognosis of Ischemic Heart Disease: Optimal Modality Across Different Patient Populations	8

Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-α Modulators and Fibrates on Microvascular Disease: Is There Still Room?	8
From Gut Inflammation to Cardiovascular Conflagration: Mapping IBD’s Cardiometabolic Risks	8
Telomere Length: Implications for Atherogenesis	8